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The Modification of Diet in Renal Disease (MDRD) Study
examined the effects of strict blood pressure control and
dietary protein restriction on the progression of kidney
disease. Here, we retrospectively evaluated outcomes of
nondiabetic participants with stages 2–4 chronic kidney
disease (CKD) from randomized and nonrandomized cohorts
of the MDRD Study. Kidney failure and survival status
through December of 2000, were obtained from the US
Renal Data System and the National Death Index. Event rates
were calculated for kidney failure, death, and a composite
outcome of death and kidney failure. In the 1666 patients,
rates for kidney failure were four times higher than that for
death. Kidney failure was a more likely event than death in
subgroups based on baseline glomerular filtration rate,
proteinuria, kidney disease etiology, gender, and race. It was
only among those older than 65 that the rate for death
approximated that for kidney failure. In contrast to other
populations with CKD, our study of relatively young subjects
with nondiabetic disease has found that the majority of the
participants advanced to kidney failure with a low competing
risk of death. In such patients, the primary emphasis should
be on delaying progression of kidney disease.
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Chronic kidney disease (CKD) is a growing public health
problem that currently affects over 20 million adults in the
United States.1,2 Globally, the increasing incidence and
prevalence of CKD is associated with adverse health
outcomes and high health-care costs.3 The two major
outcomes of patients with CKD stages 1–4 are progression
of kidney disease including development of kidney failure,
and mortality predominantly attributable to the development
of cardiovascular disease.4 There are few cohorts available
with long-term follow-up enabling a study of the clinical
epidemiology of disease progression in established CKD.
Although some studies have examined long-term outcomes
in patients with CKD,5–7 these have consisted of subgroups of
subjects with CKD in non-CKD cohorts, older subjects with
predominantly stages 1–2 CKD, and a high prevalence of
comorbid conditions including diabetes and cardiovascular
disease. There are no data of which we are aware of long-term
outcomes in patients with established CKD due to causes
other than diabetes. The objectives of this study were to
describe the natural history of a large cohort of patients with
well-characterized nondiabetic CKD, precise measurements
of kidney function, and long-term follow-up.
RESULTS
The cohort was predominantly white, relatively young, with a
slight preponderance of men, and a low baseline prevalence
of cardiovascular disease (Table 1). Polycystic kidney disease
was the etiology of CKD in approximately a quarter of the
subjects and glomerular diseases accounted for another
quarter. Range of glomerular filtration rate (GFR) was
4.9–167.8 ml per min per 1.73 m2 and proteinuria was
0.01–18 g day1. Two percent had GFR490 ml per min per
1.73m2 (stage 1 CKD), 15% had GFR 60–89 ml per min per
1.73m2 (stage 2 CKD), 46% had GFR of 30–59 ml per min
per 1.73m2 (stage 3 CKD), 28% had GFR 15–29 ml per min
per 1.73m2 (stage 4 CKD), and 9% had GFR o15 ml per
min per 1.73m2 (stage 5 CKD).
Fifty-six percent (N¼ 936) of the cohort reached kidney
failure during a median follow-up time of 88 months
(minimum of 0.03 months to a maximum of 139 months)
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and 22% (N¼ 369) died during a median follow-up time of
123 months (minimum of 0.56 months and a maximum of
140 months). We computed event rates overall, by randomi-
zation status, and by subgroups for the outcomes of kidney
failure, death, and a composite outcome of death and kidney
failure (Table 2). In the cohort as a whole, kidney failure was
a much more likely outcome than death, with the event rate
for kidney failure almost four times that for death. Kidney
failure was the more likely outcome in both the randomized
and nonrandomized cohorts. Within subgroups of baseline
GFR, rates of kidney failure and death increased with
decreasing GFR; however, at each level of GFR, kidney failure
was a more likely outcome than death. Proteinuria of
41 g day1 was associated with large increases in the rates
of both death and kidney failure; however, the latter
remained the more frequent outcome. Rates for kidney
failure were 10 times higher than those for death in patients
with polycystic kidney disease, 4 times higher for those with
glomerular disease, and twice as high for other etiologies of
kidney disease. Rates for kidney failure and death were
similar for men and women, and for blacks versus nonblacks,
and kidney failure was the more likely outcome in each of
these groups. Younger age was associated with higher rates of
progression to kidney failure. Only in the 465 years age
group did rates for death approximate those for kidney
failure.
Table 3 presents event rates by subgroups separately for
deaths occurring before and subsequent to kidney failure.
Overall and within subgroups, event rates were higher for
death subsequent to kidney failure compared with deaths
occurring before kidney failure. We calculated event rates for
kidney failure stratified by both baseline GFR and proteinur-
ia. Among individuals with baseline proteinuria p1 g day1,
event rates for kidney failure were 233, 60, and 12 per 1000
patient-years for those with GFRp24.5 (n¼ 230), 24.5–55.5
(n¼ 633), and X55.5 (n¼ 281) ml per min per 1.73 m2,
respectively. In the group with baseline proteinuria
41 g day1, event rates for kidney failure were 379, 139,
and 50 per 1000 patient-years for those with GFRp24.5
(n¼ 188), 24.5–55.5 (n¼ 235), and X55.5 (n¼ 50) ml per
min per 1.73 m2, respectively. Within each category of
baseline GFR, participants with proteinuria 41 g day1 had
higher rates of kidney failure.
Table 1 | Baseline characteristics of the cohort (N=1666)
Age (years) 49.9±12.9
Male (%) 60.2
African-American (%) 11.5
History of cardiovascular disease (%) 7.9
Etiology of CKD (%)
Polycystic kidney disease 23.2
Glomerular disease 27.3
Other 49.5
Glomerular filtration rate (ml per min per 1.73 m2) 40.0±21.0
Proteinuria (g day1) 0.25 (1.18)
Body mass index (kg m2) 27.0±4.6
Systolic blood pressure (mm Hg) 133.3±18.8
Diastolic blood pressure (mm Hg) 82.2±11.0
Data are presented as mean±s.d. or median (interquartile range).
Table 2 | Event ratesa for kidney failure, death, and the composite outcome: overall and by subgroups
N
No. of events (rate per 1000 person-years, 95% confidence intervals)
Subject group Kidney failure Deathb Composite
All patients 1666 936 (84, 79–90) 369 (23, 21–26) 1065 (96, 90–102)
Nonrandomized patients 869 415 (68, 62–75) 189 (23, 20–26) 481 (79, 72–86)
Randomized patients 797 521 (103, 95–112) 180 (24, 20–27) 797 (116, 107–125)
Baseline GFR 455.5 358 62 (18, 14–23) 31 (9, 6–12) 89 (26, 21–32)
Baseline GFR 24.5–55.5 873 479 (76, 69–83) 186 (22, 19–25) 560 (89, 81–96)
Baseline GFR p24.5 435 395 (287, 260–316) 152 (38, 32–45) 416 (303, 274–332)
Baseline urine protein p1 g day1 1144 532 (62, 57–67) 217 (19, 17–22) 636 (74, 68–80)
Baseline urine protein 41 g day1 473 378 (173, 156–191) 145 (33, 28–39) 403 (185, 167–203)
Polycystic kidney disease 387 306 (136, 122–152) 53 (14, 10–18) 312 (139, 124–155)
Glomerular disease 454 272 (95, 84–107) 100 (23, 19–28) 297 (104, 93–116)
Other 825 358 (59, 53–66) 216 (28, 24–32) 456 (76, 69–83)
Nonblacks 1474 833 (85, 79–90) 324 (23, 20–25) 944 (96, 90–102)
Blacks 192 103 (80, 65–96) 45 (25, 18–32) 121 (94, 78–112)
Male 1003 566 (88, 80–95) 251 (26, 23–30) 661 (102, 95–110)
Female 663 370 (79, 72–88) 118 (18, 15–22) 404 (87, 78–95)
Age p45 years 606 395 (102, 92–113) 41 (7, 5–9) 400 (104, 94–114)
45–65 years 837 448 (78, 71–85) 217 (28, 24–31) 523 (91, 83–99)
465 years 223 93 (61, 49–74) 111 (60, 49–71) 142 (93, 79–109)
aRates are aggregated throughout the follow-up period.
bIncludes deaths occurring before and subsequent to kidney failure.
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Figure 1 presents Kaplan–Meier curves for the three
outcomes of kidney failure, deaths occurring before kidney
failure, and the composite outcome stratified by the level of
baseline GFR. The large majority of the overall cumulative
risk of the composite outcome resulted from the cumulative
risk of the kidney events rather than death. Figure 2 presents
Kaplan–Meier curves for the composite outcome stratified by
the level of baseline GFR and proteinuria. Within each
category of GFR, the cumulative incidence of the composite
outcome was higher in participants with proteinuria
41 g day1.
Figure 3 presents kidney failure outcomes and mortality
(deaths before and after kidney failure) by deciles of baseline
GFR. Kidney failure and death increased monotonically with
decreasing level of baseline GFR. At higher GFRs, most of the
deaths occurred before kidney failure, whereas at lower levels
of GFR, the majority of deaths occurred after kidney failure.
DISCUSSION
In this study sample, derived from the randomized and
nonrandomized cohorts of the Modification of Diet in Renal
Disease (MDRD) Study, kidney failure was the most
common outcome during long-term follow-up with a low
competing risk of death, irrespective of demographic factors,
etiology of CKD, and level of baseline GFR and proteinuria.
Consistent with other studies, higher rates of progression to
kidney failure and higher rates of death were evident at lower
baseline GFR and higher proteinuria.
A few studies have attempted to examine rates for
development of kidney failure or mortality during long-term
follow-up. These have mainly entailed analyses of groups of
non-CKD patients or subgroups of patients with CKD in
non-CKD studies. In analyses from the Multiple Risk Factor
Intervention Trial that examined kidney outcomes during 16-
year follow-up in 332 544 men at high risk for cardiovascular
disease, the age-adjusted incidence of a composite of kidney
failure and kidney-related death was 35.22 per 100 000
person-years in the entire cohort, and 13.9 per 100 000
person-years (N¼ 636) for the 300 645 white participants.8
In a subsequent analysis at 25 years of follow-up, in the
randomized cohort of 12 866 men, 176 (1.4%) individuals
reached kidney failure and 37 (0.3%) died from kidney-
related causes.5 The majority of participants had GFR
X75 ml per min per 1.73 m2 and negative/trace proteinuria;
in this group, 1.3% developed kidney failure. Among
individuals with baseline estimated GFR o60 ml per min
per 1.73 m2, 4% of those with trace proteinuria, 6% of
those with 1þ proteinuria and 41% of those with 2þ
proteinuria developed kidney failure. Although these analyses
censored for death from other causes, the numbers of deaths
were not reported. A separate publication examining
mortality at 16-years follow-up in 361 662 men screened
for the Multiple Risk Factor Intervention Trial study reported
that 11% of white and 15% of black participants died of
all causes.
Hypertensive male veterans (N¼ 11 912) were identified
between 1974 and 1976 from the Veterans Administration
Hypertension Screening and Treatment Program clinics. Over
a minimum follow-up of 14 years, 5337 (45%) died and 245
(2%) developed kidney failure.9 The 15-year cumulative rate
Table 3 | Event ratesa for deaths occurring before and subsequent to kidney failure: overall and by subgroups
N
No. of events (rate per 1000 person-years, 95% confidence intervals)
Subject group Deaths before kidney failure Deaths subsequent to kidney failure
All patients 1666 129 (12, 10–14) 240 (50, 44–56)
Nonrandomized patients 869 66 (11, 8–14) 123 (55, 46–66)
Randomized patients 797 63 (13, 10–16) 117 (45, 37–53)
Baseline GFR 455.5 358 27 (8, 5–11) 4 (22, 6–48)
Baseline GFR 24.5–55.5 873 81 (13, 10–16) 105 (51, 42–61)
Baseline GFR p24.5 435 21 (15, 9–22) 131 (51, 42–60)
Baseline urine protein o1 g day1 1144 104 (12, 10–15) 113 (44, 37–53)
Baseline urine protein 41 g day1 473 25 (11, 7–16) 120 (56, 46–66)
Polycystic kidney disease 387 6 (3, 1–5) 47 (29, 21–38)
Glomerular disease 454 25 (9, 6–13) 75 (50, 39–62)
Other 825 98 (16, 13–20) 118 (69, 57–82)
Nonblacks 1474 111 (11, 9–13) 213 (50, 43–56)
Blacks 192 18 (14, 8–21) 27 (51, 33–71)
Male 1003 95 (15, 12–18) 156 (52, 44–60)
Female 663 34 (7, 5–10) 84 (46, 37–56)
Age p45 years 606 5 (1, 0–3) 36 (15, 11–20)
45–65 years 837 75 (13, 10–16) 142 (67, 57–79)
465 years 223 49 (32, 24–42) 62 (180, 138–227)
aRates are aggregated throughout the follow-up period.
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for kidney failure was 0.03 in nondiabetic and 0.06 in diabetic
participants.
An analysis from the Antihypertensive and Lipid-Low-
ering Treatment to Prevent Heart Attack Trial examined rates
of kidney failure and a composite outcome of fatal and
nonfatal cardiovascular events in high-risk hypertensive
patients over 55 years of age.7 In participants with baseline
GFR o60 ml per min per 1.73 m2, during 6 years of follow-
up, 259 (6%) participants developed kidney failure and 1954
(40%) had a fatal or nonfatal cardiovascular event. The mean
age was 71 years in this subgroup, mean estimated GFR was
approximately 50 ml per min per 1.73 m2, a third had a
history of diabetes, and over half had a history of
cardiovascular disease. Levels of proteinuria were not
available.
Analyses examining the association between body mass
index and risk of kidney failure included a cohort of adult
members of Kaiser Permanente who participated in a health
checkup from 1964 to 1985 with follow-up data on outcomes
ascertained until 2000. Among 44 583 individuals with CKD
at baseline (defined as estimated GFR o60 ml per min per
1.73 m2 or proteinuria or hematuria on dipstick), 11 768
(26%) died before reaching kidney failure. In the entire
cohort of 320 252 adult members, there was a total of 1471
cases of kidney failure and 56 336 deaths during 15–35 years
of follow-up.10,11 In another analysis from the Kaiser
Permanente registry that included 1 120 295 adults, 18% of
whom had estimated GFRo60 ml per min per 1.73 m2, there
were 3500 cases of kidney failure and 51 424 deaths.12 The
age-standardized rate of all-cause mortality ranged from 0.76
per 100 person-years in individuals with GFR X60 ml per
min per 1.73 m2 to 11.36 in those with GFR 15–29 ml per min
per 1.73 m2. Rates of kidney failure were not reported.
In each of the above-mentioned studies, mortality was a
more frequent outcome than kidney failure. The only other
study to systematically compare the competing outcomes of
kidney failure and death in subjects with established CKD,
similar to our analysis, is the one by Keith et al.6 In this study,
the authors identified 13 796 members of the Kaiser
Permanente Northwest Division health maintenance organi-
zation, with stages 2–4 CKD in 1996, and 14 202 members
with GFR 60–89 and no proteinuria (6). Staging of CKD was
based on GFR estimated from serum creatinine measure-
ments using the MDRD Study formula. Of the study cohort,
1741 had stage 2 CKD, 11 278 had stage 3 CKD, and 777 had
stage 4 CKD. Subjects were followed up until June 2001 and
vital status and transplant and dialysis were captured from
medical records. Forty-six percent of subjects with stage 4
CKD died, 2% received a transplant and 18% initiated
dialysis. For subjects with stage 3 CKD, 24% died, 0.2%
received a transplant, and 1% initiated dialysis. For those
with stage 2 CKD, 20% died, 0.2% received a transplant, and
0.9% initiated dialysis. As opposed to our findings, at every
stage of CKD, death was a more likely outcome than kidney
failure. Differences in population characteristics may account
for the contrasting results between this study and our
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Figure 1 | Kaplan–Meier curves for the three outcomes of kidney
failure (- - -), death before kidney failure ( ) and the composite
outcome ( ), stratified by level of baseline GFR. (a)
GFR¼p24.5 ml per min per 1.73 m2, (b) GFR¼ 24.5–55.5 ml per min
per 1.73 m2, (c) GFR455.5 ml per min per 1.73 m2).
Kaplan–Meier cumulative incidence curves were constructed
for the clinical composite of end-stage renal disease (ESRD) or death
during follow-up by baseline GFR groups. A competing risk approach
was used to examine the extent to which the cumulative
probabilities of the overall clinical composite reflected ESRD or death
at each follow-up time. Using the competing risk formulation,
separate cumulative incidence curves were construct to
display the cumulative probability of ESRD (without censoring death)
and of death before ESRD, without censoring the ESRD events.
The large majority of the overall cumulative risk of the composite
resulted from the cumulative risk of the kidney events rather
than death.
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findings. The Keith study cohort was older with mean age
ranging from 61 years in stage 2–74 years in stage 4 CKD.
There was a high baseline prevalence of comorbidities (56%
among patients with CKD) including diabetes and cardio-
vascular disease. In contrast, the MDRD Study cohort is
relatively young, well nourished, and nondiabetic, with lower
levels of proteinuria, a low prevalence of cardiovascular
disease and cardiovascular disease risk factors other than
hypertension, and an overrepresentation of patients with
polycystic kidney disease. All of these factors may contribute
to the low competing risk of death observed in this cohort.
These findings emphasize the fact that patients with CKD are
not a homogeneous group.
The main strength of this study is that whereas other
studies have reported on long-term outcomes in subgroups
of patients with CKD, the MDRD Study recruited patients
with recognized kidney disease from nephrology practices.
These results are generally applicable to patients with
nondiabetic CKD, but need to be interpreted in the context
of the inclusion criteria for the MDRD Study. Other strengths
are the inclusion of a large cohort of patients, long follow-up,
and precise ascertainment of baseline GFR.
In summary, although data from other cohorts suggest
that most patients with advanced CKD die before reaching
kidney failure, a large majority of younger and relatively
healthy patients with nondiabetic kidney disease, as repre-
sented by the MDRD Study cohort, will reach kidney failure.
In such patients, the primary emphasis should be on
preventing and delaying progression of kidney disease.
Further research is needed to devise strategies to retard the
development of kidney failure in this patient population.
METHODS
Details of the MDRD Study baseline cohort have been described
previously.13 Briefly, the MDRD Study, conducted between 1989 and
1993, examined the effect of dietary protein restriction and strict
blood pressure control on the rate of progression of kidney disease.
Baseline entry criteria included age between 18 and 70 years, and
serum creatinine of 1.2–7.0 mg dl1 in women and 1.4–7.0 mg dl1 in
men. Exclusion criteria were pregnancy, type 1 diabetes, insulin
dependent type 2 diabetes, autoimmune kidney diseases, obstructive
uropathy, renal artery stenosis, proteinuria greater than 10 g day1,
mean arterial pressure greater than 125 mm Hg, and previous renal
transplantation.
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Figure 2 | Kaplan–Meier curves for the composite outcome (kidney failure and deaths before and subsequent to kidney failure)
stratified by level of baseline GFR and proteinuria. Within each category of GFR, participants with proteinuria41 g day1 had higher
cumulative incidence of the composite outcome.
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Figure 3 | Kidney failure outcomes (%) and mortality (%) (deaths
before and after kidney failure) by deciles of baseline GFR. There
is a monotonic increase in kidney failure and death with decreasing
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before kidney failure, whereas at lower levels of GFR, the majority
of deaths occurred after kidney failure.
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The trial enrolled 840 participants and screened an additional
932 participants who were not randomized. There was detailed
ascertainment of baseline variables and precise measurement
of kidney function using GFR using urinary clearance of
125I-iothalamate. MDRD Study physicians assessed the etiology of
kidney disease at baseline using available clinical data. Initial
classification included 23 categories, which were subsequently
collapsed into three groups: polycystic kidney disease, glomerular
diseases, and other. The other category included the following
diagnoses: tubulointerstitial disease, urinary tract disease, hyperten-
sive nephropathy, one kidney, and unknown. We excluded 106
subjects (6%) diagnosed as having diabetic nephropathy.
We ascertained survival status from the National Death Index
and obtained kidney failure outcomes (defined as initiation of
dialysis or kidney transplantation) from the US Renal Data System.
We defined survival time for each outcome as time from
randomization or screening to kidney failure or death or end of
follow-up (December 31, 2000). The institutional review boards of
The Cleveland Clinic and Tufts-New England Medical Center
approved data-collection procedures.
Statistical analyses
In this descriptive study, we calculated event rates and its 95%
confidence interval,14 expressed as events per 1000 patient-years, for
kidney failure, death (all deaths, deaths occurring before kidney
failure, and deaths occurring subsequent to kidney failure), and a
composite outcome of death and kidney failure, overall, by
randomization status, and by subgroups of baseline factors (GFR,
proteinuria, kidney disease etiology, gender, and race), and stratified
by both baseline GFR and proteinuria. We computed event rates for
each outcome as the ratio of the number of events for that outcome
to the total patient-years of follow-up for that outcome before the
administrative censoring date of December 31, 2000. We stratified
baseline GFR stratified into o24.5, 24.5–55.5, and 455.5 ml per
min per 1.73 m2 based on inclusion criteria for the MDRD Study;
the upper limit of GFR was 55.5 and 24.55 ml per min per 1.73 m2
was the cut point for stratifying subjects in the randomized cohort
into Study A (GFR¼ 12–24.5 ml per min per 1.73 m2) and Study B
(24.5–55.5 ml per min per 1.73 m2). A competing risk approach15,16
was used to examine the extent to which the cumulative
probabilities of events for the overall clinical composite reflected
kidney failure outcomes or death at each follow-up time by baseline
GFR groups. Using the competing risk formulation, we constructed
separate cumulative incidence curves to display the cumulative
probability of kidney failure (without censoring death) and of death
before kidney failure, without censoring the kidney events. In this
way, at each follow-up time point, the two-component cumulative
incidence curves (for kidney events and death before kidney failure,
respectively) approximately add to the cumulative incidence for the
overall composite. We constructed Kaplan–Meier cumulative
incidence curves for the clinical composite of kidney failure or
death (deaths before and after kidney failure), stratified by baseline
GFR and proteinuria. We also plotted the overall proportions of
kidney failure outcomes and mortality (deaths before and
after kidney failure) by deciles of baseline GFR. For simplicity, we
are presenting rates aggregated throughout the follow-up period. In
certain cases, variations over time were noted.
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